MLL-Rearranged Acute Lymphoblastic Leukemias Activate BCL-2 through H3K79 Methylation and Are Sensitive to the BCL-2-Specific Antagonist ABT-199

[1]  N. Zeleznik-Le,et al.  Degree of recruitment of DOT1L to MLL-AF9 defines level of H3K79 Di- and tri-methylation on target genes and transformation potential. , 2015, Cell reports.

[2]  S. Molica Highlights in the treatment of chronic lymphocytic leukemia from the 2014 meeting of the American Society of Hematology , 2015, Expert review of hematology.

[3]  T. Chambers,et al.  BH3 Inhibitor Sensitivity and Bcl-2 Dependence in Primary Acute Lymphoblastic Leukemia Cells. , 2015, Cancer research.

[4]  Dolores Diaz,et al.  Exploiting selective BCL-2 family inhibitors to dissect cell survival dependencies and define improved strategies for cancer therapy , 2015, Science Translational Medicine.

[5]  John G Doench,et al.  DOT1L inhibits SIRT1-mediated epigenetic silencing to maintain leukemic gene expression in MLL-rearranged leukemia , 2015, Nature Medicine.

[6]  Cheng Cheng,et al.  The landscape of somatic mutations in Infant MLL rearranged acute lymphoblastic leukemias , 2015, Nature Genetics.

[7]  F. Behm,et al.  Intensified chemotherapy without SCT in infant ALL: Results from COG P9407 (Cohort 3) , 2015, Pediatric blood & cancer.

[8]  A. Letai,et al.  Cell and Molecular Determinants of In Vivo Efficacy of the BH3 Mimetic ABT-263 against Pediatric Acute Lymphoblastic Leukemia Xenografts , 2014, Clinical Cancer Research.

[9]  M. Loh,et al.  Maturation stage of T-cell acute lymphoblastic leukemia determines BCL-2 versus BCL-XL dependence and sensitivity to ABT-199. , 2014, Cancer discovery.

[10]  J. Cayuela,et al.  Oncogenetics and minimal residual disease are independent outcome predictors in adult patients with acute lymphoblastic leukemia. , 2014, Blood.

[11]  A. Letai,et al.  Selective BCL-2 inhibition by ABT-199 causes on-target cell death in acute myeloid leukemia. , 2014, Cancer discovery.

[12]  Matthew E. Ritchie,et al.  Targeting BCL-2 with the BH3 mimetic ABT-199 in estrogen receptor-positive breast cancer. , 2013, Cancer cell.

[13]  N. Heerema,et al.  Potent obatoclax cytotoxicity and activation of triple death mode killing across infant acute lymphoblastic leukemia. , 2013, Blood.

[14]  S. Cory,et al.  ABT-199, a new Bcl-2-specific BH3 mimetic, has in vivo efficacy against aggressive Myc-driven mouse lymphomas without provoking thrombocytopenia. , 2013, Blood.

[15]  Thomas A. Milne,et al.  RUNX1 Is a Key Target in t(4;11) Leukemias that Contributes to Gene Activation through an AF4-MLL Complex Interaction , 2013, Cell reports.

[16]  T. Cierpicki,et al.  Leukemia fusion target AF9 is an intrinsically disordered transcriptional regulator that recruits multiple partners via coupled folding and binding. , 2013, Structure.

[17]  L. Lam,et al.  ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets , 2013, Nature Medicine.

[18]  J. Naval,et al.  Direct Interaction of Bax and Bak Proteins with Bcl-2 Homology Domain 3 (BH3)-only Proteins in Living Cells Revealed by Fluorescence Complementation* , 2013, The Journal of Biological Chemistry.

[19]  I. Jeremias,et al.  In Vivo Imaging Enables High Resolution Preclinical Trials on Patients’ Leukemia Cells Growing in Mice , 2012, PloS one.

[20]  Michael C. Rusch,et al.  Abstract 4869: Whole genome sequence analysis of MLL rearranged infant acute lymphoblastic leukemias reveals remarkably few somatic mutations: A Report From the St Jude Children's Research Hospital - Washington University Pediatric Cancer Genome Project , 2012 .

[21]  R. Lock,et al.  Pharmacokinetic Modeling of an Induction Regimen for In Vivo Combined Testing of Novel Drugs against Pediatric Acute Lymphoblastic Leukemia Xenografts , 2012, PloS one.

[22]  F. Peale,et al.  Navitoclax (ABT-263) Reduces Bcl-xL–Mediated Chemoresistance in Ovarian Cancer Models , 2012, Molecular Cancer Therapeutics.

[23]  J. Hess,et al.  MLL-ENL inhibits polycomb repressive complex 1 to achieve efficient transformation of hematopoietic cells. , 2011, Cell reports.

[24]  Steven M Kornblau,et al.  Abnormal expression of FLI1 protein is an adverse prognostic factor in acute myeloid leukemia. , 2011, Blood.

[25]  S. Robson,et al.  Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia , 2011, Nature.

[26]  H. Maecker,et al.  The Bcl-2/Bcl-XL/Bcl-w Inhibitor, Navitoclax, Enhances the Activity of Chemotherapeutic Agents In Vitro and In Vivo , 2011, Molecular Cancer Therapeutics.

[27]  C. Allis,et al.  Function of leukemogenic mixed lineage leukemia 1 (MLL) fusion proteins through distinct partner protein complexes , 2011, Proceedings of the National Academy of Sciences.

[28]  Adam R. Johnson,et al.  Sensitivity to antitubulin chemotherapeutics is regulated by MCL1 and FBW7 , 2011, Nature.

[29]  Sebastian Herzog,et al.  BCL6 enables Ph+ acute lymphoblastic leukemia cells to survive BCR-ABL1 kinase inhibition , 2011, Nature.

[30]  J. Zha,et al.  Navitoclax Enhances the Efficacy of Taxanes in Non–Small Cell Lung Cancer Models , 2011, Clinical Cancer Research.

[31]  T. Dingermann,et al.  The AF4.MLL fusion protein is capable of inducing ALL in mice without requirement of MLL.AF4. , 2010, Blood.

[32]  A. Shilatifard,et al.  Linking H3K79 trimethylation to Wnt signaling through a novel Dot1-containing complex (DotCom). , 2010, Genes & development.

[33]  A. Roberts,et al.  The Bcl-2 Homology Domain 3 Mimetic ABT-737 Targets the Apoptotic Machinery in Acute Lymphoblastic Leukemia Resulting in Synergistic in Vitro and in Vivo Interactions with Established Drugs , 2010, Molecular Pharmacology.

[34]  M. Cleary,et al.  A higher-order complex containing AF4 and ENL family proteins with P-TEFb facilitates oncogenic and physiologic MLL-dependent transcription. , 2010, Cancer cell.

[35]  A. Shilatifard,et al.  AFF4, a component of the ELL/P-TEFb elongation complex and a shared subunit of MLL chimeras, can link transcription elongation to leukemia. , 2010, Molecular cell.

[36]  J. Testa,et al.  FAS-Associated Factor 1 (FAF1): Diverse functions and implications for oncogenesis , 2009, Cell cycle.

[37]  T. Volkert,et al.  Aberrant chromatin at genes encoding stem cell regulators in human mixed-lineage leukemia. , 2008, Genes & development.

[38]  Xiaobo Xia,et al.  H3K79 methylation profiles define murine and human MLL-AF4 leukemias. , 2008, Cancer cell.

[39]  C. Felix,et al.  Abundant anti‐apoptotic BCL‐2 is a molecular target in leukaemias with t(4;11) translocation , 2008, British journal of haematology.

[40]  S. Armstrong,et al.  BCL-2 dependence and ABT-737 sensitivity in acute lymphoblastic leukemia. , 2008, Blood.

[41]  A. Chinnaiyan,et al.  A role for the MLL fusion partner ENL in transcriptional elongation and chromatin modification. , 2007, Blood.

[42]  R. Lock,et al.  Activity of vincristine, L-ASP, and dexamethasone against acute lymphoblastic leukemia is enhanced by the BH3-mimetic ABT-737 in vitro and in vivo. , 2007, Blood.

[43]  R. Pieters,et al.  A treatment protocol for infants younger than 1 year with acute lymphoblastic leukaemia (Interfant-99): an observational study and a multicentre randomised trial , 2007, The Lancet.

[44]  S. Armstrong,et al.  Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family members. , 2006, Cancer cell.

[45]  P. Hadwiger,et al.  Targeting MLL-AF4 with short interfering RNAs inhibits clonogenicity and engraftment of t(4;11)-positive human leukemic cells. , 2005, Blood.

[46]  L. Lam,et al.  Souers AJ, Leverson JD, Boghaert ER et al.ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med 19:202-208 , 2013 .

[47]  K. Zhao,et al.  Chromatin immunoprecipitation (ChIP) for analysis of histone modifications and chromatin-associated proteins. , 2009, Methods in molecular biology.